Download the Prospectus
Pre Money Equity Valuation
Min Raise
Max Raise
Estimated Close
Issue Type
Lead Manager
Canaccord Genuity
Type of Securities
Date First Lodged
Offer Costs $
Market Cap Max
Key Executives
Jonathan West (NEC), Michael Aldridge (MD and CEO), Nicole van der Weerden (ED), Marilyn Anderson (ED), Scott Robertson (NED), Justin Yap (NED)
Company Address
Level 4, LIMS2, La Trobe University Melbourne Victoria 3086
Chairman's Letter

Dear Investor,
On behalf of the Board, I am pleased to offer you this opportunity to invest in
Hexima Limited.
Hexima is developing a novel topical treatment, HXP124, for fungal nail infections
(onychomycosis). Onychomycosis is a common condition which is estimated to
affect up to 14% of the population in North America and is also common in Asian
and European populations. Current treatment options do not adequately meet
patient needs, requiring long treatment durations, delivering modest efficacy and/or
carrying a risk of severe side effects.
Hexima considers that HXP124 offers the potential to be a global leader in this
market, with a superior cure rate, shorter treatment time and/or fewer side effects
than existing oral and topical options. Hexima’s antifungal technology may also be
applicable to a broader range of human fungal diseases.
The proceeds of the Offer will be used to conduct an Australian phase IIb clinical
trial to assess the safety, tolerability and efficacy of HXP124 as a topical treatment
for onychomycosis. Proceeds will also be used to scale-up manufacturing of HXP124
and to conduct animal toxicology studies required to support late-stage clinical
trials in the US.
Through this Prospectus, the Company is inviting investors to subscribe for
15,000,000 New Shares, at an Offer Price of $0.20 per Share to raise $3,000,000
(before costs and expenses of the Offer). Existing Shareholders will also have the
opportunity to sell their shares through a Share Sale Facility.
This Prospectus contains detailed information about the Offer, the historical position
of Hexima and the material risks associated with an investment in the Company. You
should be aware that an investment in Hexima is a highly speculative investment
given that the Company has not generated any product revenue on HXP124, its lead
development candidate and is not currently generating a positive cash flow.
I encourage you to read and understand the Prospectus, and seek independent
professional advice as necessary, before making an investment decision.
I look forward to welcoming you as a Shareholder.
Yours sincerely
Professor Jonathan West
Hexima Limited